Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma
- PMID: 16965897
- DOI: 10.1016/j.ijom.2006.06.016
Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma
Abstract
Oral squamous cell carcinoma (OSCC) is the most common malignant tumour in the oral and maxillofacial region, and has a poor prognosis. Cyfra 21-1 is a useful tumour marker for squamous cell carcinoma, but the clinical value of Cyfra 21-1 in OSCC has not been confirmed. In order to investigate the diagnostic and prognostic value of serum Cyfra 21-1 in primary OSCC patients, the preoperative serum Cyfra 21-1 concentration of 100 OSCC patients and 56 healthy subjects was detected by enzyme-linked immunosorbent assay (ELISA). The cut-off value was calculated with a receiver operating characteristic (ROC) curve, and prognostic analysis was performed using the Kaplan-Meier method and Cox regression models. The preoperative serum Cyfra 21-1 concentration in OSCC patients (1.18+/-1.20 microg/L) was significantly higher (t=6.585, P<0.001) than that in healthy subjects (0.40+/-0.16 microg/L). With a cut-off value of 0.65 microg/L, the diagnostic sensitivity and specificity was 0.570 and 0.964, respectively. There was significant correlation with tumour recurrence and survival rate: the higher the serum Cyfra 21-1; the higher the tumour recurrence rate and lower the survival rate. Serum Cyfra 21-1 was an independent prognostic factor for OSCC using univariate and multivariate Cox models.
Similar articles
-
Increased Cyfra 21-1 concentration in saliva from primary oral squamous cell carcinoma patients.Arch Oral Biol. 2007 Nov;52(11):1079-87. doi: 10.1016/j.archoralbio.2007.05.005. Epub 2007 Jul 5. Arch Oral Biol. 2007. PMID: 17612501
-
Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.Anticancer Res. 1997 May-Jun;17(3C):2329-34. Anticancer Res. 1997. PMID: 9245246
-
Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma.Anticancer Res. 2009 Aug;29(8):3421-5. Anticancer Res. 2009. PMID: 19661367
-
The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.Crit Rev Oncol Hematol. 2008 Apr;66(1):10-20. doi: 10.1016/j.critrevonc.2007.09.002. Epub 2007 Oct 26. Crit Rev Oncol Hematol. 2008. PMID: 17964182 Review.
-
[CYFRA 21-1 and bronchial cancer].Rev Mal Respir. 1995;12(6):533-41. Rev Mal Respir. 1995. PMID: 8677347 Review. French.
Cited by
-
Diagnostic values of serum tumor markers Cyfra21-1, SCCAg, ferritin, CEA, CA19-9, and AFP in oral/oropharyngeal squamous cell carcinoma.Onco Targets Ther. 2016 Jun 3;9:3381-6. doi: 10.2147/OTT.S105672. eCollection 2016. Onco Targets Ther. 2016. PMID: 27350753 Free PMC article.
-
Upregulation of Synuclein-γ and Snai1 Contributes to Poor Clinical Prognosis in Oral Squamous Cell Carcinoma Patients.Biomed Res Int. 2022 Apr 7;2022:6534626. doi: 10.1155/2022/6534626. eCollection 2022. Biomed Res Int. 2022. PMID: 35434126 Free PMC article.
-
Serum markers of CYFRA 21-1 and C-reactive proteins in oral squamous cell carcinoma.World J Surg Oncol. 2015 Aug 21;13:253. doi: 10.1186/s12957-015-0656-9. World J Surg Oncol. 2015. PMID: 26292957 Free PMC article.
-
Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma.Tumour Biol. 2016 Jul;37(7):9263-71. doi: 10.1007/s13277-016-4809-4. Epub 2016 Jan 15. Tumour Biol. 2016. PMID: 26779624
-
Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis.PLoS One. 2019 May 9;14(5):e0216561. doi: 10.1371/journal.pone.0216561. eCollection 2019. PLoS One. 2019. PMID: 31071161 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical